Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Perceive Biotherapeutics, Inc.
Study ID
NCT06087458
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VOY-101 — BIOLOGICAL
    VOY-101

Study Details

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Key Dates

Start date
Jun 21, 2023
Status verified
Sep 2025
Primary completion
Jun 30, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: VOY-101
    Single intravitreal injection of VOY-101
  • No Intervention: Controll
    Fellow Eye

Primary Outcome Measure

Overall effect of treatment on retinal structural health [ Time Frame: Week 48 ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Retina Macula Institute of AZScottsdaleArizona85255-
The Retina PartnersEncinoCalifornia91436-
Retinal Consultants Medical GroupSacramentoCalifornia95825-
Retina Consultants San DiegoSan DiegoCalifornia92064-
Star RetinaBurlesonTexas76028-
Retina Center of TexasSouthlakeTexas76092-
University of Utah John A. Moran Eye CenterSalt Lake CityUtah84132-

Find similar trials in Scottsdale, AZ

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Retina Macula Institute of AZ· Scottsdale, AZThe Retina Partners· Encino, CARetinal Consultants Medical Group· Sacramento, CARetina Consultants San Diego· San Diego, CAStar Retina· Burleson, TXRetina Center of Texas· Southlake, TX

Related Studies